SciCross is a full member of the Innovative Medicines Initiative (IMI) project ABIRISK. Within the ABIRISK project, we collect and analyze both retrospective and prospective immunogencity-related data from a large number of patients. The disease areas covered includes hemophilia A, rheumatoid arthritis and inflammatory bowel disease, all areas where biopharmaceuticals (BPs) are used as treatment. SciCross is leading the database subteam responsible for collecting and integrating data from clinical studies, ADA assays, PK/PD assays, immunophenotyping etc. Furthermore, SciCross contributes in the integration and analysis of data generate wrt T-cell epitopes and activation. For further information please visit the ABIRISK website.

Selected ABIRISK publications

Bachelet D, Hässler S, Mbogning C, et al. Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS ONE. 2016;11(11):e0162752.Pubmed: 27806057

Link J, Ramanujam R, Auer M, et al. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE. 2017;12(2):e0170395. Pubmed: 28170401

Schultz et al., Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay, PLoS One. 2017 May 31; 12(5), PMID: 28562666

Adriani et al., Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients, JCI Insight. 2018 Jun 7;3(11). Pubmed: 29875313

Bitoun et al., Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann Rheum Dis. 2018 Oct;77(10):1463-1470.  Pubmed: 29936438

Quistrebert et al., Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Semin Arthritis Rheum. 2018 Oct 12. pii: S0049-0172(18)30176-8. Pubmed: 30420245

Jensen et al., Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. J Neuroimmunol. 2019 Jan 15;326:19-27. Pubmed: 30447419

van der Weele et al., Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis, J Neuroimmunol. 2022 Sep 15;370:577932, 35853357